NEW YORK, NY / ACCESS Newswire / January 31, 2025 / Levi & Korsinsky notifies investors that it has commenced an investigation of Vertex ...

17:51 EST Vertex Pharmaceuticals (VRTX)’ non-opioid painkiller approved by FDA, Bloomberg says Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news.

For example, the Vertex Pharmaceuticals Incorporated (NASDAQ:VRTX) share price is up 83% in the last five years, slightly above the market return. Over the last year the stock price is up ...

Vertex Pharmaceuticals (VRTX) closed at $428 in the latest trading session, marking a +0.03% move from the prior day. The stock's change was less than the S&P 500's daily gain of 0.61%.

Despite healthcare sector struggles, Vertex Pharmaceuticals has outperformed both its biotech peers and the broader market since 2022. The company dominates the cystic fibrosis market and is ...

Shares of Vertex Pharmaceuticals VRTX5.31%increase; green up pointing triangle rose after Journavx, the company’s oral non-opioid pain medication, received Food and Drug Administration approval.

Shares of Vertex Pharmaceuticals rose after Journavx, the company's oral non-opioid pain medication, received Food and Drug Administration approval. The Boston company's stock rose 4.3% ...

Vertex Pharmaceuticals Inc. (NASDAQ:VRTX), a leading biotechnology company specializing in cystic fibrosis (CF) treatments, has been making significant strides in expanding its therapeutic ...

Jan 30 (Reuters) - The U.S. Food and Drug Administration has approved Vertex Pharmaceuticals' (VRTX.O), opens new tab drug to treat acute pain, the health regulator said on Thursday, offering a ...